Calcified, retroflexed subtotal long occlusion of left circumflex into OM1 successfully intervened after lithotripsy via left distal radial (anatomical) snuffbox approach

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability

Nicola Ryan provides her take on the final results of OPT-BIRISK which were presented by Yaling Han during the ESC 2023 congress in Amsterdam.

Note the assumptions in this article are based on the presentation alone as the trial has not yet been published.

Reported from ACC 2023 / WCC

Edoardo Zancanaro provides his take on this clinical trial presented by Enoch Akowuah at the American College of Cardiology Scientific Session (ACC.23/WCC).

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Drug-coated balloon (DCB) angioplasty has become a valuable alternative to drug-eluting stents in treating coronary artery disease. To achieve optimal outcomes, proper lesion preparation and techniques to minimise drug loss are crucial.

This article highlights key steps and best practices for performing DCB angioplasty, ensuring effective drug delivery and...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Ali Nazmi Calik provides his take on the results of the PREVENT trial presented at ACC.24 in Atlanta.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Paris, France. 19 May 2022. We CARE, a joint initiative of PCR and Stent – Save a Life!, dedicated to restoring faith in cardiovascular healthcare and increasing awareness of the importance of timely and accessible treatment, is presenting a first study at EuroPCR 2022: a UK...

Mirvat Alasnag provides her take on the Altshock-2 randomized clinical trial which was presented by Alice Sacco at ACC.25 in Chicago.

Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.